Table 1 Basic characteristics and treatment regimens in patients with NHL and persistent vs. non-persistent SARS-CoV-2 infections

Age (years)

55.2 ± 12.8

45.1 ± 10.5

< 0.001

Sex (M/F)

60/50

277/273

0.32

Hypertension

71 (64.5%)

192 (34.9%)

< 0.001

Diabetes

33 (30.0%)

108 (19.6%)

0.002

Immunosuppressed State

76 (69.1%)

76 (13.8%)

< 0.001

Lymphocyte Count (×10⁹/L)

0.7 ± 0.4

1.2 ± 0.6

< 0.001

C-Reactive Protein (mg/L)

53.5 ± 14.1

20.3 ± 10.5

< 0.001

Body Mass Index (BMI)

27.5 ± 4.1

24.3 ± 3.8

< 0.001

Average Disease Duration (d)

28.0 ± 12.1

10.0 ± 4.1

< 0.001

Renal Insufficiency

49 (44.5%)

53 (9.6%)

< 0.001

Anemia

35 (31.8%)

78 (14.2%)

< 0.001

COVID-19 Vaccination

89 (80.9%)

431 (78.4%)

0.34

Number of Vaccinations

2.5 ± 0.8

2.7 ± 0.6

0.08

Comparison of Treatment Regimens

Antiviral Treatment

91 (82.7%)

407 (74.0%)

0.55

Immunomodulators

46 (41.8%)

207 (37.6%)

0.32

Respiratory Support

18 (16.4%)

82 (14.9%)

0.68

Steroid Treatment

25 (22.7%)

106 (19.3%)

0.38

Anticoagulation Therapy

48 (43.6%)

211 (38.4%)

0.15

Comparison of Specific Antiviral Drugs

Nirmatrelvir/Ritonavir

51 (46.4%)

247 (44.9%)

0.98

Xenutide/Ritonavir

29 (26.4%)

148 (26.9%)

0.45

Molnupiravir

26 (23.6%)

99 (18.0%)

0.40

Azvudine

14 (12.7%)

77 (14.0%)

0.75